Why Breakthrough Therapies Need Biz Dev Thinking Before the Market Is Ready

Jul 01, 2026

8 min read

1 views

68%

The Real Bottleneck Is Not Discovery, It Is Demand

What if the hardest part of launching a breakthrough therapy is not proving it works, but proving the world is ready to use it?

That is the uncomfortable truth hidden inside every ambitious therapeutic launch. A treatment can be scientifically elegant, clinically compelling, and commercially important, yet still stall if the surrounding market is not built for it. In other words, the product may be ready long before the system is.

That is why the most useful way to think about advanced therapies like CAR T is not just as medical innovations, but as market experiments. A therapy does not enter a market fully formed. It enters an ecosystem of physicians, referral pathways, manufacturing limits, reimbursement rules, patient selection, and institutional trust. The companies that win are often not the ones with the most exciting science alone, but the ones that learn how to shape demand as carefully as they shape molecules and cells.

A Therapy Is Not a Product Until the Market Can Absorb It

At first glance, CAR T seems like a manufacturing story. Engineers build the cells, clinicians administer them, and patients receive transformative care. But the commercial reality is more complicated. A therapy can be clinically approved and still treat only a fraction of the eligible population if hospitals are slow to adopt it, physicians lack familiarity, or manufacturing cannot scale.

That is where the deeper analogy with business development becomes powerful. In a company’s early life, engineering improves the product, while biz dev runs experiments on the market. The same logic applies to breakthrough medicines. Clinical development asks, “Can this work?” Market development asks, “Can this be absorbed?” Those are not the same question.

For CD19 CAR T, the answer is increasingly yes, but only because the market has been taught how to say yes. Early approvals created proof. Later approvals created familiarity. Expanding labels create new use cases. Every step reduces friction for the next one. A therapy that once felt extraordinary gradually becomes part of the routine infrastructure of oncology.

This is why the projected growth matters less as a sales story than as a signal of market maturation. If annual treated patients rise from thousands to over thirteen thousand across major markets, that is not merely a bigger pie. It is evidence that the system surrounding the therapy has learned how to handle complexity at scale.

A breakthrough therapy does not scale when the science is convincing. It scales when the surrounding market becomes teachable.

The Hidden Competition Is Between Adoption Curves, Not Just Molecules

It is tempting to think the battle among therapies is a contest of efficacy alone. In reality, the contest is between adoption curves. The first product to establish clinical trust often gains an advantage that is much harder to dislodge than a modest efficacy edge.

This is especially true in complex treatments like CAR T, where physicians do not simply prescribe a pill. They initiate a process that involves patient identification, referral timing, coordination with specialized centers, and management of toxicity. Every additional layer raises the cost of switching. Once a therapy becomes embedded in workflows, it benefits from inertia, not just preference.

That is why first movers can retain leadership even as competition intensifies. The advantage is not only temporal, it is organizational. A hospital that has built protocols around one CAR T product, trained its staff, and gained confidence in outcomes is less likely to change course without a compelling reason. In this sense, market share is partly a memory effect.

This also explains why label expansion matters so much. Expanding into earlier lines of therapy is not merely a regulatory event. It is a bid to move upstream in the treatment journey, before clinicians have already settled on a default. If a therapy waits too long, it becomes trapped in the later line economy, where patients are fewer, urgency is different, and adoption often depends on salvage logic rather than first-choice logic.

Think of it like restaurant seating. The first table near the window is not better because of taste alone. It is better because it is visible, easy to occupy, and likely to stay occupied. Early line therapy is the window table of oncology.

Why Manufacturing Is Not a Back-Office Problem, It Is Strategy

The most revealing part of this landscape is not the enthusiasm for expansion. It is the uncertainty around manufacturing capacity.

That detail should stop any strategist in their tracks. When demand rises faster than production, the constraint is no longer theoretical. The ceiling becomes physical. If a therapy can only be produced at a certain rate, then every label expansion is also a stress test of operational design.

This creates a profound business development lesson: market opportunity is only real if supply can meet it. In advanced therapies, biz dev cannot be separated from manufacturing. The promise of a new indication is not just, “Can we treat more patients?” but also, “Can we reliably manufacture enough product, in time, with acceptable quality, and with a distribution model that supports adoption?”

This is where many companies misunderstand scale. They assume demand follows clinical success automatically. In truth, demand is often created by a sequence of confidence-building events:

Clinicians see real-world data.
Treatment centers gain operational fluency.
Payers accept the economics.
Referral networks normalize the therapy.
Manufacturing proves it can keep up.

If any one of these fails, the growth curve bends.

The best strategic operators know this. They do not treat capacity as a back-office issue to solve later. They treat it as a core part of the product promise. In a field where time to treatment matters, a therapy that cannot be delivered consistently is not merely inconvenient, it is commercially fragile.

Market Development Is a Sequence of Trust Transfers

One reason these therapies grow so slowly at first, then accelerate, is that adoption depends on a chain of trust. Each participant must trust the one before them.

The patient must trust the physician. The physician must trust the data. The hospital must trust the workflow. The payer must trust the value. The manufacturer must trust its own throughput. Each layer is a separate adoption problem, and each layer can slow the whole system.

This is a useful framework for understanding why certain therapies win over time even when they face competition from newer entrants. The winner is often not the most novel option, but the one that has already completed the hardest work of trust transfer. By the time a physician is comfortable recommending it, and a center is comfortable delivering it, and a payer is comfortable reimbursing it, the therapy has become much more than a drug. It has become a platform in practice.

This helps explain why novel cell therapies may be forced into later lines until evidence accumulates. In medicine, credibility compounds slowly. New entrants must not only prove efficacy, but also earn permission to displace a known workflow. That is a much heavier lift than many product teams assume.

A useful mental model here is to imagine each launch as a relay race. Science hands off to regulation, regulation hands off to clinical practice, clinical practice hands off to hospital operations, and operations hand off to reimbursement. If one runner drops the baton, the whole race slows. Business development is the discipline of making every handoff more reliable.

The Best Strategy Is to Create the Market You Want to Serve

Here is the deeper synthesis: the future leaders in advanced therapies will not simply respond to demand. They will manufacture demand conditions.

That does not mean manipulating the market. It means building the evidence, infrastructure, and operational confidence that make broader adoption rational. In plain terms, this is what good business development looks like in healthcare. It is not a side function that sits after science. It is the mechanism by which science becomes scalable value.

For CD19 CAR T, the key strategic moves are clear. Move earlier when the evidence supports it. Expand into additional indications where the biology fits. Invest in physician familiarity and site readiness. Align manufacturing with forecasted uptake. Use robust data to reduce the perceived risk of adoption. Each of these actions is a market experiment designed to lower friction.

This is why the most important question is not, “Which product is best?” but, “Which team can make the market ready for its product fastest?” That question captures the real competitive edge in breakthrough healthcare. It rewards not just discovery, but orchestration.

Seen this way, market leadership looks less like a trophy and more like an institutional capability. The winners are the organizations that learn how to turn one successful use case into a repeatable adoption pattern. They do not just sell a therapy. They build the conditions under which the therapy can keep selling itself.

Key Takeaways

Breakthrough science does not automatically create breakthrough adoption. The market must be prepared through trust, workflow, reimbursement, and operational readiness.
Biz dev in advanced therapies is really market experimentation. The goal is to discover which conditions make adoption repeatable and scalable.
First-mover advantage is often a trust advantage. Once clinicians, hospitals, and payers normalize a therapy, later entrants face an uphill battle even if they are strong products.
Manufacturing capacity is strategic, not operational. If supply cannot match demand, label expansion becomes a ceiling instead of a growth engine.
The best companies shape the market they want to win. They do not wait for demand to appear; they create the evidence and infrastructure that make demand possible.

The Endgame Is Not Just More Patients, It Is a New Default

The most important shift in thinking is this: the goal is not merely to treat more patients. The goal is to change what the market considers normal.

That is the real prize in any transformative therapy. Not a one time spike in usage, but a new default pathway in clinical decision making. Once a treatment moves from exceptional to expected, the market has been truly won. The science may have started the journey, but business development, in the deepest sense, is what finishes it.

And that is the lesson that reaches far beyond oncology. Any company bringing something complex, unfamiliar, and potentially world changing to market must learn the same truth: the product is only half the innovation. The market is the other half, and it must be built, tested, and trained.